Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab
The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.
Authors
- Hirohito Umeno (ORCID: https://orcid.org/0000-0002-2347-495X)
- Takeharu Ono (ORCID: https://orcid.org/0000-0003-2414-7034)
- Mioko Fukahori
- T. Mitsuhashi (ORCID: https://orcid.org/0009-0007-6635-891X)
- Fumihiko Satô (ORCID: https://orcid.org/0000-0002-7990-7590)
- Shintaro Sueyoshi (ORCID: https://orcid.org/0000-0003-4261-3019)
- Akira Hiraki (ORCID: https://orcid.org/0009-0009-7851-3678)
- Toshihiko Kawaguchi (ORCID: https://orcid.org/0000-0003-2754-0202)
- Tsunehiro Oka
- Takashi Kurita (ORCID: https://orcid.org/0000-0001-9593-4612)
- Shun‐ichi Chitose (ORCID: https://orcid.org/0000-0002-9307-2331)
- Masahiro Seki
- Hisaichiro Tanaka
- K. Sato
- Masayasu Naito
- Itaru Mizobe
Institutions
- Kurume University (JP)
- Omuta hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-08-28
- DOI
- https://doi.org/10.21873/anticanres.17757
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00